The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts

被引:77
作者
Nikpour, M. [1 ]
Scharenberg, C. [1 ,2 ]
Liu, A. [1 ]
Conte, S. [1 ]
Karimi, M. [1 ]
Mortera-Blanco, T. [1 ]
Giai, V. [1 ]
Fernandez-Mercado, M. [3 ]
Papaemmanuil, E. [4 ]
Hogstrand, K. [1 ]
Jansson, M. [1 ]
Vedin, I. [1 ]
Wainscoat, J. Stephen [3 ]
Campbell, P. [4 ,5 ]
Cazzola, M. [6 ,7 ]
Boultwood, J. [3 ]
Grandien, A. [1 ]
Hellstrom-Lindberg, E. [1 ]
机构
[1] Karolinska Univ Hosp Huddinge, Dept Med, Ctr Hematol & Regenerat Med, Karolinska Inst, S-14186 Stockholm, Sweden
[2] Skaraborgs Hosp, Dept Med, Skovde, Sweden
[3] John Radcliffe Hosp, LLR Mol Haematol Unit, NDCLS, Oxford OX3 9DU, England
[4] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England
[5] Univ Cambridge, Dept Haematol, Cambridge, England
[6] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[7] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy
基金
英国惠康基金;
关键词
acquired sideroblastic anemia; RARS; ABCB7; SF3B1; iron sulfur cluster biogenesis; mitochondrial ferritin (FTMT); MYELODYSPLASTIC SYNDROMES; SF3B1; MUTATIONS; GENE; CELLS; EXPRESSION; MACHINERY; APOPTOSIS; PATHWAY; ATAXIA;
D O I
10.1038/leu.2012.298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Refractory anemia with ring sideroblasts (RARS) is characterized by mitochondrial ferritin (FTMT) accumulation and markedly suppressed expression of the iron transporter ABCB7. To test the hypothesis that ABCB7 is a key mediator of ineffective erythropoiesis of RARS, we modulated its expression in hematopoietic cells. ABCB7 up and downregulation did not influence growth and survival of K562 cells. In normal bone marrow, ABCB7 downregulation reduced erythroid differentiation, growth and colony formation, and resulted in a gene expression pattern similar to that observed in intermediate RARS erythroblasts, and in the accumulation of FTMT. Importantly, forced ABCB7 expression restored erythroid colony growth and decreased FTMT expression level in RARS CD34+ marrow cells. Mutations in the SF3B1 gene, a core component of the RNA splicing machinery, were recently identified in a high proportion of patients with RARS and 11 of the 13 RARS patients in this study carried this mutation. Interestingly, ABCB7 exon usage differed between normal bone marrow and RARS, as well as within the RARS cohort. In addition, SF3B1 silencing resulted in downregulation of ABCB7 in K562 cells undergoing erythroid differentiation. Our findings support that ABCB7 is implicated in the phenotype of acquired RARS and suggest a relation between SF3B1 mutations and ABCB7 downregulation. Leukemia (2013) 27, 889-896; doi:10.1038/leu.2012.298
引用
收藏
页码:889 / 896
页数:8
相关论文
共 36 条
[1]   Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A) [J].
Allikmets, R ;
Raskind, WH ;
Hutchinson, A ;
Schueck, ND ;
Dean, M ;
Koeller, DM .
HUMAN MOLECULAR GENETICS, 1999, 8 (05) :743-749
[2]   The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts [J].
Boultwood, Jacqueline ;
Pellagatti, Andrea ;
Nikpour, Maryam ;
Pushkaran, Beena ;
Fidler, Carrie ;
Cattan, Helen ;
Littlewood, Tim J. ;
Malcovati, Luca ;
Della Porta, Matteo G. ;
Jadersten, Martin ;
Killick, Sally ;
Giagounidis, Aristoteles ;
Bowen, David ;
Hellstrom-Lindberg, Eva ;
Cazzola, Mario ;
Wainscoat, James S. .
PLOS ONE, 2008, 3 (04)
[3]   Hereditary Sideroblastic Anemias: Pathophysiology, Diagnosis, and Treatment [J].
Camaschella, Clara .
SEMINARS IN HEMATOLOGY, 2009, 46 (04) :371-377
[4]   RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload [J].
Cavadini, Patrizia ;
Biasiotto, Giorgio ;
Poli, Maura ;
Levi, Sonia ;
Verardi, Rosanna ;
Zanella, Isabella ;
Derosas, Manuela ;
Ingrassia, Rosaria ;
Corrado, Marcella ;
Arosio, Paolo .
BLOOD, 2007, 109 (08) :3552-3559
[5]   Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia [J].
Cazzola, M ;
Invernizzi, R ;
Bergamaschi, G ;
Levi, S ;
Corsi, B ;
Travaglino, E ;
Rolandi, V ;
Biasiotto, G ;
Drysdale, J ;
Arosio, P .
BLOOD, 2003, 101 (05) :1996-2000
[6]   SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications [J].
Damm, F. ;
Thol, F. ;
Kosmider, O. ;
Kade, S. ;
Loeffeld, P. ;
Dreyfus, F. ;
Stamatoullas-Bastard, A. ;
Tanguy-Schmidt, A. ;
Beyne-Rauzy, O. ;
de Botton, S. ;
Guerci-Bresler, A. ;
Goehring, G. ;
Schlegelberger, B. ;
Ganser, A. ;
Bernard, O. A. ;
Fontenay, M. ;
Heuser, M. .
LEUKEMIA, 2012, 26 (05) :1137-1140
[7]   Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes [J].
Graubert, Timothy A. ;
Shen, Dong ;
Ding, Li ;
Okeyo-Owuor, Theresa ;
Lunn, Cara L. ;
Shao, Jin ;
Krysiak, Kilannin ;
Harris, Christopher C. ;
Koboldt, Daniel C. ;
Larson, David E. ;
McLellan, Michael D. ;
Dooling, David J. ;
Abbott, Rachel M. ;
Fulton, Robert S. ;
Schmidt, Heather ;
Kalicki-Veizer, Joelle ;
O'Laughlin, Michelle ;
Grillot, Marcus ;
Baty, Jack ;
Heath, Sharon ;
Frater, John L. ;
Nasim, Talat ;
Link, Daniel C. ;
Tomasson, Michael H. ;
Westervelt, Peter ;
DiPersio, John F. ;
Mardis, Elaine R. ;
Ley, Timothy J. ;
Wilson, Richard K. ;
Walter, Matthew J. .
NATURE GENETICS, 2012, 44 (01) :53-U77
[8]  
Hellstrom-Lindberg Eva, 2008, Hematology Am Soc Hematol Educ Program, P52, DOI 10.1182/asheducation-2008.1.52
[9]   Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF [J].
Jädersten, M ;
Montgomery, SM ;
Dybedal, I ;
Porwit-MacDonald, A ;
Hellström-Lindberg, E .
BLOOD, 2005, 106 (03) :803-811
[10]   High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms [J].
Jeromin, Sabine ;
Haferlach, Torsten ;
Grossmann, Vera ;
Alpermann, Tamara ;
Kowarsch, Andreas ;
Haferlach, Claudia ;
Kern, Wolfgang ;
Schnittger, Susanne .
HAEMATOLOGICA, 2013, 98 (02) :E15-E17